House Bill 1527 seeks to establish protections for 340B entities and the drugs they provide by prohibiting discriminatory practices from drug manufacturers, health insurance issuers, and pharmacy benefit managers (PBMs) in Florida. The bill introduces new sections in the Florida Statutes that define "340B drug" and "340B entity," and it specifically prohibits drug manufacturers from interfering with the acquisition and delivery of 340B drugs to contracted pharmacies. Additionally, it mandates that insurers and PBMs cannot reimburse 340B entities at lower rates than non-340B entities and cannot impose different terms or conditions based on the 340B status of the entity.

The legislation classifies violations of these prohibitions as deceptive and unfair trade practices under the Florida Deceptive and Unfair Trade Practices Act, which subjects violators to penalties. It also clarifies that these provisions do not apply to the Medicaid program regarding reimbursement for covered outpatient drugs. The bill aims to ensure equitable treatment for 340B entities, enhancing their ability to provide affordable medications to patients, and is set to take effect on July 1, 2025.